Basit öğe kaydını göster

dc.contributor.authorArslan, Melikşah
dc.contributor.authorBahadır, Zeynep
dc.contributor.authorBasiaga, Matthew L.
dc.contributor.authorChalmers, Sarah J.
dc.contributor.authorDemirel, Nadir
dc.date.accessioned2024-01-15T09:47:09Z
dc.date.available2024-01-15T09:47:09Z
dc.date.issued2023en_US
dc.identifier.citationArslan, M., Bahadır, Z., Basiaga, M. L., Chalmers, S. J. ve Demirel, N. (2023). A pediatric cystic fibrosis arthropathy case who responded to Elexacaftor/ Tezacaftor/Ivacaftor therapy. Journal of Cystic Fibrosis, 22(6), 1120-1122. https://dx.doi.org/10.1016/j.jcf.2023.08.012en_US
dc.identifier.issn1569-1993
dc.identifier.issn1873-5010
dc.identifier.urihttps://dx.doi.org/10.1016/j.jcf.2023.08.012
dc.identifier.urihttps://hdl.handle.net/20.500.12511/12139
dc.description.abstractCystic fibrosis arthropathy (CFA) is a transient, intermittent form of arthritis that cannot be associated with any other disease other than CF thus making CFA a diagnosis of exclusion. NSAIDs, short-term intermittent splinting, glucocorticoids, and disease-modifying anti-rheumatic drugs are treatment options for CFA. Currently, there is no consensus on how to best treat CFA. Diagnosis and treatment of CFA remain a challenge for physicians and people with CF. The newest CFTR modulator therapy, elexacaftor/tezacaftor/ivacaftor (ETI), was approved by the FDA recently for children over the age of 6 with at least one Phe508del allele in the CFTR gene. Multiple clinical benefits of ETI in pulmonary functions and overall disease burden have been reported since its approval, however, the data on the musculoskeletal therapeutic benefits of ETI has been limited. In this report, we present a 7-year-old female with CF whose CFA symptoms resolved after starting ETI therapy.en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectArthropathyen_US
dc.subjectCFTR Modulatorsen_US
dc.subjectCystic Fibrosisen_US
dc.subjectElexacaftor/Tezacaftor/Ivacaftoren_US
dc.subjectInflammatory Arthritisen_US
dc.subjectMusculoskeletal Symptomsen_US
dc.subjectNSAIDsen_US
dc.titleA pediatric cystic fibrosis arthropathy case who responded to Elexacaftor/ Tezacaftor/Ivacaftor therapyen_US
dc.typearticleen_US
dc.relation.ispartofJournal of Cystic Fibrosisen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalıen_US
dc.identifier.volume22en_US
dc.identifier.issue6en_US
dc.identifier.startpage1120en_US
dc.identifier.endpage1122en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.1016/j.jcf.2023.08.012en_US
dc.institutionauthorBahadır, Zeynep
dc.identifier.wosqualityQ2en_US
dc.identifier.wos001128633200001en_US
dc.identifier.scopus2-s2.0-85171381039en_US
dc.identifier.pmid37709627en_US
dc.identifier.scopusqualityQ1en_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster